47 results
8-K
EX-99.5
KANT
Kineta, Inc.
22 Dec 22
Kineta Completes Reverse Merger with Yumanity Therapeutics
5:02pm
, packaging, distribution, storage, advertising, promotion, import, export, recordkeeping, monitoring and reporting for Kineta’s product will be subject
8-K
EX-99.6
KANT
Kineta, Inc.
22 Dec 22
Kineta Completes Reverse Merger with Yumanity Therapeutics
5:02pm
, development, testing, manufacture, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, marketing … for testing the identity, strength, quality and purity of the final drug. In addition, appropriate packaging must be selected and tested and stability
424B3
wnkhq mnwfv5jihg7
10 Nov 22
Prospectus supplement
4:21pm
425
oza decozm
6 Jun 22
Business combination disclosure
4:05pm
8-K
EX-2.1
havt0u yf94uvdhb
6 Jun 22
Yumanity Therapeutics Announces Definitive Agreements for Two Strategic Transactions
4:02pm